Most cases of HFS are caused by a vascular loop that compresses the root exit zone of the facial nerve where it emerges from the brainstem. Some rare causes of HFS, such as tumors and vascular malformations, have also been identified. Authors of several large case series have reported that symptomatic HFS resulting from mass lesions occurs infrequently, in 0.4%–0.8% of cases.5,6,13,20,22 Most cases of tumor-related HFS are treated satisfactorily by open resection of the tumor alone or combined with vascular decompression.5,6,9,12,13,15,16,20 Radiosurgery is now used successfully to treat brain tumors related to hyperfunction of the trigeminal nerve.5,18,19,23 Since the incidence of tumor-related HFS is very low, only a few cases treated with surgery or radiosurgery have been reported.8,10,17 In the present report we describe outcomes in 6 patients treated by GKS for tumor-related HFS with a mean follow-up of 84 months.

Methods

Patient Population

Between 2000 and 2011, 6 patients (5 women and 1 man) with benign tumor–related HFS were treated with the Leksell Gamma Knife (Elekta AB) at our institution. The mean age of the patients at the time of radiosurgery was 52.7 years (range 45–60 years). The patients’ tumors lay within the radiosurgical target area. In the 4 cases of meningioma, the mean radiosurgical treatment volume was 5.3 cm³ (range 1.2–9.6 cm³), and the mean radiosurgical tumor margin dose was 14.1 Gy (range 12–18 Gy); in the 2 cases of VS, the treatment volume was 2.5 cm³ in 1 patient and 11.2 cm³ in the other, and the mean margin doses were 11.5 and 12 Gy, respectively. The mean duration of HFS symptoms was 15.5 months (range 3–36 months).

Results

The mean follow-up period was 84 months (range 40–110 months). Overall, 4 (66%) of the 6 patients experienced complete relief from HFS without medication after GKS and 1 patient obtained a good outcome. The mean time for improvement to be realized was 12.6 months (range 3–24 months). Only 1 patient failed to experience relief from HFS, and coincidentally, the tumor did not shrink in that case. In all 6 patients (100%), tumor growth was controlled at a mean follow-up of 56 months after GKS: in 5 patients the tumor had decreased in size and in the other patient the tumor size remained unchanged. No new neurological deficit was noted after GKS, and 1 patient with facial numbness reported improvement after tumor shrinkage.

Conclusions

Gamma Knife surgery appears to be effective in treating benign tumor–related HFS and in controlling tumor growth. A reduction in tumor volume is related to spasm improvement. Although a time latency for spasm relief is associated with GKS, minimal side effects are expected.

Key Words • acoustic neuroma • stereotactic radiosurgery • hemifacial spasm

Abbreviations used in this paper: CPA = cerebellopontine angle; GKS = Gamma Knife surgery; HFS = hemifacial spasm; VS = vestibular schwannoma.
Gamma Knife surgery for tumor-related hemifacial spasm

the primary treatment; 3 patients had associated symptoms of hearing impairment or loss, and 1 had trigeminal nerve pain and abducence nerve palsy. The median duration of HFS before GKS was 15.5 months (range 3–36 months). The follow-up period ranged from 40 to 110 months (median 84 months). Patient characteristics in this group are summarized in Table 1.

Radiosurgical Technique

In all 6 cases the Leksell stereotactic coordinate frame (Elekta AB) was applied after the patient had received a local anesthetic agent supplemented with a mild sedative. Stereotactic Gd-enhanced MR imaging, in which 1-mm slice intervals were obtained with volume acquisition, was performed during radiosurgery to determine target coordinates and for dose planning. A 201-source cobalt Gamma Knife unit was used for radiosurgery. The radiation volume was determined and shaped to the tumor margin in all 6 patients by using an average of 14 isocenters (range 8–23 isocenters). In the 4 cases of meningioma, the mean radiosurgical treatment volume was 5.3 cm³ (range 1.2–9.6 cm³), and the mean radiosurgical tumor margin dose was 14.1 Gy (range 12–18 Gy); in the 2 cases of VS, the radiation volume was 2.5 cm³ in 1 patient and 11.8 cm³ in the other, and the margin doses were 11.5 and 12 Gy, respectively.

Clinical Assessments

We subdivided clinical outcomes into 4 categories: excellent, good, fair, and poor. Complete spasm relief after GKS without the use of any medication was defined as an excellent outcome. Patients whose relief from spasm intensity or frequency was more than 90% were considered to have a good outcome. Patients with partial spasm relief (>50%–90% pain relief) were considered to have a fair outcome. No spasm relief or less than 50% relief was considered a poor outcome.

Results

The follow-up period ranged from 40 to 110 months (mean 84 months). The outcomes of spasm and other cranial nerve defects are detailed in Table 1. Overall, 4 (66.7%) of the 6 patients experienced excellent outcomes and 1 patient (16.7%) had a good outcome without medication after GKS. Spasm improvement occurred at a mean follow-up time of 12.6 months (range 3–24 months). One patient (16.7%) had a poor outcome.

Follow-up MR images showed control of tumor growth in all 6 patients (100%) at a mean of 84 months after GKS. In 5 patients (83%) the tumor was smaller than it had been at the time of GKS; all 5 patients eventually experienced spasm improvement (Figs. 1 and 2).

One patient experienced relief from trigeminal nerve pain and excellent spasm relief simultaneously without any improvement in her abducence nerve palsy. The improvements were associated with tumor shrinkage. Three patients with hearing impairment before GKS did not experience an improvement in hearing function.

Discussion

Most cases of HFS are believed to be caused by vascular compression, but in rare cases, HFS can be caused by tumors. In our experience thus far, cases of tumor-related HFS constituted 2% of all meningiomas and 1.8% of VSs treated by GKS. In a group of 1642 patients with HFS who underwent microsurgery, Han et al. reported that 7 patients (0.4%) harbored tumors. Han et al. reported that 2 (6.7%) of 30 enlarged VSs and 2% of 337 patients with hearing impairment before GKS did not experience an improvement in hearing function.

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs), Sex</th>
<th>Tumor Type</th>
<th>Duration of HFS Pre-GKS (mos)</th>
<th>Rad Vol (cm³)</th>
<th>Margin Dose (Gy)</th>
<th>Onset of Improv/Improved Gone (mos)</th>
<th>Outcome/Other Deficits</th>
<th>Tumor Vol Change</th>
<th>Other Deficits</th>
<th>FU Time (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60, F men</td>
<td>meningioma</td>
<td>36</td>
<td>9.6</td>
<td>13.4</td>
<td>12/18</td>
<td>E/—</td>
<td>↓</td>
<td>TNP, ANP</td>
<td>110</td>
</tr>
<tr>
<td>2</td>
<td>60, F men</td>
<td>meningioma</td>
<td>36</td>
<td>5.3</td>
<td>18</td>
<td>18/60</td>
<td>E/—</td>
<td>↓↓↓</td>
<td>HA, tinnitus</td>
<td>105</td>
</tr>
<tr>
<td>3</td>
<td>51, F VS</td>
<td>VS</td>
<td>11</td>
<td>2.5</td>
<td>11.5</td>
<td>—/—</td>
<td>P/—</td>
<td>NC</td>
<td>Hi, tinnitus</td>
<td>85</td>
</tr>
<tr>
<td>4</td>
<td>50, F men</td>
<td>meningioma</td>
<td>3</td>
<td>1.2</td>
<td>13</td>
<td>3/3</td>
<td>E/—</td>
<td>↓</td>
<td>HA, FN</td>
<td>74</td>
</tr>
<tr>
<td>5</td>
<td>45, F men</td>
<td>meningioma</td>
<td>4</td>
<td>5.3</td>
<td>12</td>
<td>6/—</td>
<td>G/—</td>
<td>↓</td>
<td>Hi</td>
<td>75</td>
</tr>
<tr>
<td>6</td>
<td>50, M VS</td>
<td>meningioma</td>
<td>3</td>
<td>11.8</td>
<td>12</td>
<td>24/36</td>
<td>E/—</td>
<td>↓↓↓</td>
<td>HL</td>
<td>40</td>
</tr>
</tbody>
</table>

* ANP = abducent nerve palsy; E = excellent; FN = facial numbness; FU = follow up; G = good; HA = headache; HI = hearing impairment; HL = hearing loss; Improv = improvement; men = meningioma; NC = no change; P = poor; Rad = radiation; TP = trigeminal nerve pain; ↓ = 25%–50% volume reduction; ↓↓ = 51%–75% volume reduction; ↓↓↓ = more than 75% volume reduction; — = not applicable.
Régis et al.\textsuperscript{19} noted HFS in 3\% of their patients with VSs following treatment with GKS.

**Mechanism of Spasm Relief After Microsurgery and Radiosurgery**

The most common cause of HFS is compression of the nerve root by a vascular loop. Only a few cases of compression include tumors, cysts, or vascular malformations as the causative agent.\textsuperscript{3,5,6,9,11–13,15,16,20,21} One hypothesis is that tumors induce local compression of the facial nerve root exit zone. According to a few reports on large tumors distal to the facial nerve, vascular compression is a reasonable explanation for the incidence of HFS.\textsuperscript{2} Samii and Matthies\textsuperscript{20} demonstrated that small VSs and cranial nerve vascular loop compression coexist intraoperatively. An explanation for the favorable result achieved using microsurgery may be that the tumor debulking achieved with resection rapidly relieves pressure on the facial nerve root.\textsuperscript{20} As for radiosurgery, we observed that in all cases of improvement there was decreased tumor size. Two patients experienced cessation of spasms 30 and 48 months after tumor shrinkage. Pollock\textsuperscript{18} reported the occurrence of new facial spasm due to tumor enlargement in 6 patients 13–26 months (median 20 months) after radiosurgery. This finding provides evidence that tumor size is directly related to facial spasm. Moreover, we also observed that 2 patients experienced spasm relief before marked shrinkage of the tumor volume, and in 2 other patients the time latency of spasm improvement lasted as long as 1.5 years. Since the initial improvement in spasm occurred earlier than tumor shrinkage in these 2 patients, the mechanisms of spasm relief induced by GKS for HFS may be similar to those for idiopathic trigeminal neuralgia. Radiation-induced blockage of the paroxysmal ephaptic transmission in idiopathic trigeminal neuralgia may serve as an explanation for the relief from HFS after GKS. Fraioli et al.\textsuperscript{4} reported preliminary results of treatment of idiopathic HFS using radiosurgery or stereotactic hypofractionated radiotherapy and showed that a low radiation dose (8 Gy) directed to the facial nerve improved HFS. Kida et al.\textsuperscript{10} observed improvement in 5 of 7 pa-

---

**Fig. 1.** A: Axial enhanced MR image obtained before GKS in a 60-year-old woman who harbored a meningioma. B: Marked shrinkage of the tumor 8 years after GKS. C: Photograph showing the patient’s HFS before GKS. D: Photograph showing complete relief from HFS 5 years post-GKS.

**Fig. 2.** Magnetic resonance images. A: An enhanced image obtained in a 45-year-old man before GKS showing a VS (volume 11.8 cm$^3$). B: Despite the fact that there is no shrinkage of tumor 6 months post-GKS, there is a loss of central enhancement in the tumor region. C: Evidence of tumor shrinkage (volume 6 cm$^3$) 2 years after GKS. The patient’s HFS was markedly improved but had not resolved completely. D: Further shrinkage of tumor (volume 3.9 cm$^3$). The patient’s HFS disappeared 3 years post-GKS.
Gamma Knife surgery for tumor-related hemifacial spasm

tients with facial or trigeminal nerve hyperfunction, de-
spite the fact that tumor shrinkage was confirmed in only
two patients. Peker and coworkers\(^7\) observed complete
disappearance of facial spasm 12 months after a VS was
treated by GKS with 13 Gy delivered to the tumor mar-
gin, despite the fact that the tumor volume remained the
same at the 22-month follow-up. That case indicates that
GKS may be an option for tumor-related HFS.

Outcomes of Microsurgery and Radiosurgery

Tumor removal is by far the most effective means of
relieving tumor-induced HFS in patients who are able to
undergo such a procedure safely. Unfortunately, due to
the rarity of tumor-induced HFS, only a handful of case
reports have been published (Table 2). Of 7 patients in
whom a tumor was removed, 6 (86%) experienced to-
total relief of pain, as reported by Han et al.\(^6\) Samii and
Matthies\(^20\) demonstrated excellent long-term results and
freedom from spasm at a mean follow-up time of 9 years
in 4 patients with VSs. Nagata et al.\(^16\) noted excellent
postoperative recovery after resection of benign tumors
in the posterior fossa in their 4 patients (100%). Iwai et
al.\(^8\) reported 2 cases, in which one patient had undergone
microsurgery alone and the other patient had microsur-
gery followed by radiosurgery for residual tumor. Both
patients obtained freedom from HFS.

In the literature, there are only 2 published cases of
benign tumors associated with HFS that were treated by
radiosurgery. Peker et al.\(^17\) described a case of VS with
disappearance of spasm. Kida and colleagues\(^10\) reported
another case involving an epidermoid cyst; in that study
the patient also obtained freedom from HFS.

Morbid conditions related to cranial nerves, such as
new facial paresis or numbness, are rarely seen in patients
who have undergone radiosurgery for skull base tumors.
Similar results were observed in our small patient group
harboring VSs or CPA meningiomas. In patients treated
by microsurgery, transient or permanent facial paresis
is relatively high: 9 (10%) of 86 cases have been noted,
and other cranial nerve injuries have also been reported
(Table 2).

As to the onset of improvement, most patients treated
by radiosurgery experienced improvement in association
with tumor shrinkage, although there was a lag phase of
3–24 months. In patients treated by microsurgery, most
patients experienced immediate improvement.

Conclusions

Gamma Knife surgery can be effective in treating
tumor-related HFS and controlling tumor growth, espe-
cially in cases of CPA meningiomas and VSs. Although
a lag phase for spasm relief exists, minimal side effects
are expected.

Disclosure

The authors report no conflict of interest concerning the mate-
rials or methods used in this study or the findings specified in this
paper.

Author contributions to the study and manuscript preparation
include the following. Conception and design: Huang, Chang.
Acquisition of data: Chang, Tu. Analysis and interpretation of data:
Chang, Chuang. Drafting the article: Huang, Chang. Critical revi-
sion of the article: all authors. Reviewed submitted version of manu-
script: all authors. Approved the final version of the manuscript
on behalf of all authors: Huang. Statistical analysis: Chang, Chuang, Tu,
Liu. Administrative/technical/material support: Chang, Liu. Study
supervision: Huang.

TABLE 2: Microsurgical and radiosurgical cases in the treatment of CPA tumor–related HFS

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No. of Patients</th>
<th>No. of Patients Stratified by Tumor Pattern</th>
<th>No. of Patients Stratified by Type of Surgery</th>
<th>Follow-Up (mos)</th>
<th>No. of Patients Stratified by HFS Outcome</th>
<th>No. of Patients Stratified by Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miyazaki et al., 1983, 1987</td>
<td>2</td>
<td>1 men, 1 EC</td>
<td>MS</td>
<td>8, 16</td>
<td>2 disappeared</td>
<td>1 HL, 1 FP, 1 HO</td>
</tr>
<tr>
<td>Nagata et al., 1992</td>
<td>4</td>
<td>1 EC, 2 men, 1 VS</td>
<td>MS</td>
<td>NA</td>
<td>4 disappeared</td>
<td>1 FP</td>
</tr>
<tr>
<td>Samii &amp; Matthies, 1995</td>
<td>4</td>
<td>4 VS</td>
<td>MS</td>
<td>108</td>
<td>4 disappeared</td>
<td>1 FP</td>
</tr>
<tr>
<td>Kobata et al., 2002</td>
<td>2</td>
<td>2 EC</td>
<td>MS</td>
<td>150</td>
<td>2 good</td>
<td>2 HI, 1 FN, 1 ANP</td>
</tr>
<tr>
<td>Iwai et al., 2003</td>
<td>2</td>
<td>2 men</td>
<td>1 MS, 1 MS + RS</td>
<td>NA</td>
<td>2 disappeared</td>
<td>1 FP</td>
</tr>
<tr>
<td>Peker et al. 2004</td>
<td>1</td>
<td>1 VS</td>
<td>RS</td>
<td>22</td>
<td>1 disappeared</td>
<td>none</td>
</tr>
<tr>
<td>Kida et al., 2006</td>
<td>1</td>
<td>1 EC</td>
<td>RS</td>
<td>NA</td>
<td>1 disappeared</td>
<td>none</td>
</tr>
<tr>
<td>Barajas et al., 2009</td>
<td>1</td>
<td>1 L</td>
<td>MS</td>
<td>NA</td>
<td>1 disappeared</td>
<td>none</td>
</tr>
<tr>
<td>Han et al., 2009</td>
<td>7</td>
<td>3 EC, 1 VS, 2 L, 1 AC</td>
<td>MS</td>
<td>NA</td>
<td>6 disappeared (1 repeated MVD)</td>
<td>1 FP, 1 HL</td>
</tr>
<tr>
<td>Han et al., 2010</td>
<td>55</td>
<td>41 EC, 7 men, 7 VS</td>
<td>MS</td>
<td>NA</td>
<td>43 disappeared</td>
<td>2 FP, 6 HI, 2 HO</td>
</tr>
<tr>
<td>Lee et al., 2010</td>
<td>9</td>
<td>5 men, 2 VS, 2 EC</td>
<td>MS</td>
<td>NA</td>
<td>7 disappeared</td>
<td>2 FP</td>
</tr>
<tr>
<td>current series</td>
<td>6</td>
<td>4 men, 2 VS</td>
<td>RS</td>
<td>84 (mean)</td>
<td>4 disappeared, 1 improved</td>
<td>none</td>
</tr>
</tbody>
</table>

* AC = arachnoid cyst; EC = epidermoid cyst; FP = facial palsy; HO = hoarseness; L = lipoma; MS = microsurgery; MVD = microvascular decompres-
sion; NA = not analyzed; RS = radiosurgery.
References


